Cargando…
A randomized pilot trial evaluating safety and immunogenicity of recMAGE-A3 + AS15 immunotherapeutic administered by intramuscular versus intradermal/subcutaneous routes
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288705/ http://dx.doi.org/10.1186/2051-1426-2-S3-P60 |
| _version_ | 1782352009444196352 |
|---|---|
| author | Slingluff, Craig L Petroni, Gina R Olson, Walter C Chianese-bullock, Kimberly A Smith, Kelly T Smolkin, Mark E Galeassi, Nadedja Grosh, William Weiss, Geoffrey Scott, Kristy Hornillo, Ana |
| author_facet | Slingluff, Craig L Petroni, Gina R Olson, Walter C Chianese-bullock, Kimberly A Smith, Kelly T Smolkin, Mark E Galeassi, Nadedja Grosh, William Weiss, Geoffrey Scott, Kristy Hornillo, Ana |
| author_sort | Slingluff, Craig L |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4288705 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2014 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-42887052015-01-15 A randomized pilot trial evaluating safety and immunogenicity of recMAGE-A3 + AS15 immunotherapeutic administered by intramuscular versus intradermal/subcutaneous routes Slingluff, Craig L Petroni, Gina R Olson, Walter C Chianese-bullock, Kimberly A Smith, Kelly T Smolkin, Mark E Galeassi, Nadedja Grosh, William Weiss, Geoffrey Scott, Kristy Hornillo, Ana J Immunother Cancer Poster Presentation BioMed Central 2014-11-06 /pmc/articles/PMC4288705/ http://dx.doi.org/10.1186/2051-1426-2-S3-P60 Text en Copyright © 2014 Slingluff et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Slingluff, Craig L Petroni, Gina R Olson, Walter C Chianese-bullock, Kimberly A Smith, Kelly T Smolkin, Mark E Galeassi, Nadedja Grosh, William Weiss, Geoffrey Scott, Kristy Hornillo, Ana A randomized pilot trial evaluating safety and immunogenicity of recMAGE-A3 + AS15 immunotherapeutic administered by intramuscular versus intradermal/subcutaneous routes |
| title | A randomized pilot trial evaluating safety and immunogenicity of recMAGE-A3 + AS15 immunotherapeutic administered by intramuscular versus intradermal/subcutaneous routes |
| title_full | A randomized pilot trial evaluating safety and immunogenicity of recMAGE-A3 + AS15 immunotherapeutic administered by intramuscular versus intradermal/subcutaneous routes |
| title_fullStr | A randomized pilot trial evaluating safety and immunogenicity of recMAGE-A3 + AS15 immunotherapeutic administered by intramuscular versus intradermal/subcutaneous routes |
| title_full_unstemmed | A randomized pilot trial evaluating safety and immunogenicity of recMAGE-A3 + AS15 immunotherapeutic administered by intramuscular versus intradermal/subcutaneous routes |
| title_short | A randomized pilot trial evaluating safety and immunogenicity of recMAGE-A3 + AS15 immunotherapeutic administered by intramuscular versus intradermal/subcutaneous routes |
| title_sort | randomized pilot trial evaluating safety and immunogenicity of recmage-a3 + as15 immunotherapeutic administered by intramuscular versus intradermal/subcutaneous routes |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288705/ http://dx.doi.org/10.1186/2051-1426-2-S3-P60 |
| work_keys_str_mv | AT slingluffcraigl arandomizedpilottrialevaluatingsafetyandimmunogenicityofrecmagea3as15immunotherapeuticadministeredbyintramuscularversusintradermalsubcutaneousroutes AT petroniginar arandomizedpilottrialevaluatingsafetyandimmunogenicityofrecmagea3as15immunotherapeuticadministeredbyintramuscularversusintradermalsubcutaneousroutes AT olsonwalterc arandomizedpilottrialevaluatingsafetyandimmunogenicityofrecmagea3as15immunotherapeuticadministeredbyintramuscularversusintradermalsubcutaneousroutes AT chianesebullockkimberlya arandomizedpilottrialevaluatingsafetyandimmunogenicityofrecmagea3as15immunotherapeuticadministeredbyintramuscularversusintradermalsubcutaneousroutes AT smithkellyt arandomizedpilottrialevaluatingsafetyandimmunogenicityofrecmagea3as15immunotherapeuticadministeredbyintramuscularversusintradermalsubcutaneousroutes AT smolkinmarke arandomizedpilottrialevaluatingsafetyandimmunogenicityofrecmagea3as15immunotherapeuticadministeredbyintramuscularversusintradermalsubcutaneousroutes AT galeassinadedja arandomizedpilottrialevaluatingsafetyandimmunogenicityofrecmagea3as15immunotherapeuticadministeredbyintramuscularversusintradermalsubcutaneousroutes AT groshwilliam arandomizedpilottrialevaluatingsafetyandimmunogenicityofrecmagea3as15immunotherapeuticadministeredbyintramuscularversusintradermalsubcutaneousroutes AT weissgeoffrey arandomizedpilottrialevaluatingsafetyandimmunogenicityofrecmagea3as15immunotherapeuticadministeredbyintramuscularversusintradermalsubcutaneousroutes AT scottkristy arandomizedpilottrialevaluatingsafetyandimmunogenicityofrecmagea3as15immunotherapeuticadministeredbyintramuscularversusintradermalsubcutaneousroutes AT hornilloana arandomizedpilottrialevaluatingsafetyandimmunogenicityofrecmagea3as15immunotherapeuticadministeredbyintramuscularversusintradermalsubcutaneousroutes AT slingluffcraigl randomizedpilottrialevaluatingsafetyandimmunogenicityofrecmagea3as15immunotherapeuticadministeredbyintramuscularversusintradermalsubcutaneousroutes AT petroniginar randomizedpilottrialevaluatingsafetyandimmunogenicityofrecmagea3as15immunotherapeuticadministeredbyintramuscularversusintradermalsubcutaneousroutes AT olsonwalterc randomizedpilottrialevaluatingsafetyandimmunogenicityofrecmagea3as15immunotherapeuticadministeredbyintramuscularversusintradermalsubcutaneousroutes AT chianesebullockkimberlya randomizedpilottrialevaluatingsafetyandimmunogenicityofrecmagea3as15immunotherapeuticadministeredbyintramuscularversusintradermalsubcutaneousroutes AT smithkellyt randomizedpilottrialevaluatingsafetyandimmunogenicityofrecmagea3as15immunotherapeuticadministeredbyintramuscularversusintradermalsubcutaneousroutes AT smolkinmarke randomizedpilottrialevaluatingsafetyandimmunogenicityofrecmagea3as15immunotherapeuticadministeredbyintramuscularversusintradermalsubcutaneousroutes AT galeassinadedja randomizedpilottrialevaluatingsafetyandimmunogenicityofrecmagea3as15immunotherapeuticadministeredbyintramuscularversusintradermalsubcutaneousroutes AT groshwilliam randomizedpilottrialevaluatingsafetyandimmunogenicityofrecmagea3as15immunotherapeuticadministeredbyintramuscularversusintradermalsubcutaneousroutes AT weissgeoffrey randomizedpilottrialevaluatingsafetyandimmunogenicityofrecmagea3as15immunotherapeuticadministeredbyintramuscularversusintradermalsubcutaneousroutes AT scottkristy randomizedpilottrialevaluatingsafetyandimmunogenicityofrecmagea3as15immunotherapeuticadministeredbyintramuscularversusintradermalsubcutaneousroutes AT hornilloana randomizedpilottrialevaluatingsafetyandimmunogenicityofrecmagea3as15immunotherapeuticadministeredbyintramuscularversusintradermalsubcutaneousroutes |